Diamyd diabetes vaccine: Phase III completed enrollment

The company completed enrollment of 320 patients aged 10-20 recently diagnosed with Type I diabetes in a double-blind, placebo-controlled, European Phase III trial evaluating subcutaneous Diamyd. The ...